Selective intracellular delivery of proteasome inhibitors through pH-sensitive polymeric micelles directed to efficient antitumor therapy

Journal of Controlled Release

Volumn 188, Issue , 2014, Pages 67-77

  Quader, S ^a   Cabral, H ^a   Mochida, Y ^a   Ishii, T ^a   Liu, X ^b   Toh, K ^a   Kinoh, H ^a   Miura, Y ^b   Nishiyama, N ^c   Kataoka, K ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

Antitumor efficacy; MG132; pH sensitive; Polymeric micelle; Proteasome inhibitor

Indexed keywords

CELL CULTURE; CELL DEATH; CRITICAL MICELLE CONCENTRATION; CYTOTOXICITY; FUNCTIONAL POLYMERS; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES; TUMORS; VIDEO RECORDING;

ANTI-TUMOR EFFICACY; MG132; PH SENSITIVE; POLYMERIC MICELLE; PROTEASOME INHIBITORS;

MICELLES;

ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; COPOLYMER; HYDRAZONE DERIVATIVE; MACROGOL; POLYASPARTIC ACID; BENZYLOXYCARBONYLLEUCYL-LEUCYL-LEUCINE ALDEHYDE; DELAYED RELEASE FORMULATION; LEUPEPTIN; MICELLE; POLYMER; PROTEASOME INHIBITOR;

ACETYLATION; AMINOLYSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; BREAST CANCER CELL LINE; CANCER CELL LINE; CELL COMPARTMENTALIZATION; CELLULAR DISTRIBUTION; CERVICAL CANCER CELL LINE; CONFOCAL LASER MICROSCOPY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CRITICAL MICELLE CONCENTRATION; CROSS LINKING; CULTURE MEDIUM; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; ENDOSOME; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; INTRACELLULAR SPACE; LIGHT SCATTERING; LIMIT OF QUANTITATION; LYSOSOME; MALE; MESOTHELIOMA CELL LINE; MICELLE; MICELLIZATION; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PH; POLYMERIZATION; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; PROTON NUCLEAR MAGNETIC RESONANCE; REAL TIME POLYMERASE CHAIN REACTION; RING OPENING; STEREOSPECIFICITY; TARGET CELL; TIMED DRUG RELEASE; TRANSMISSION ELECTRON MICROSCOPY; TUMOR MODEL; TUMOR VOLUME; UTERINE CERVIX CANCER; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DELAYED RELEASE FORMULATION; NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; LEUPEPTINS; MICE, INBRED BALB C; MICELLES; NEOPLASMS; POLYMERS; PROTEASOME INHIBITORS;

EID: 84903522158     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.05.048     Document Type: Article

References (50)

1. P. Brooks, G. Fuertes, R.Z. Murray, S. Bose, E. Knecht, M.C. Rechsteiner, K.B. Hendil, K. Tanaka, J. Dyson, and A.J. Rivett Subcellular localization of proteasomes and their regulatory complexes in mammalian cells Biochem. J. 346 2000 155 161 (Pubitemid 30113832)
2. A.F. Kisselev, W.A. van der Linden, and H.S. Overkleeft Proteasome inhibitors: an expanding army attacking a unique target Chem. Biol. 19 2012 99 115
3. J. Adams The proteasome: a suitable antineoplastic agent Nat. Rev. Cancer 4 2004 349 360
4. R.C. Kane, R. Dagher, A. Farrell, C.-W. Ko, R. Sridhara, R. Justice, and R. Pazdur Bortezomib for the treatment of mantle cell lymphoma Clin. Cancer Res. 13 2007 5291 5294 (Pubitemid 47510352)
5. A.L. Goldberg Development of proteasome inhibitors as research tools and cancer drugs J. Cell Biol. 199 2012 583 588
6. K.L. Rock, C. Gramm, L. Rothstein, K. Clark, R. Stein, L. Dick, D. Hwang, and A.L. Goldberg Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules Cell 78 1994 761 771 (Pubitemid 24294452)
7. D.H. Lee, and A.L. Goldberg Selective inhibitors of the proteasome-dependent and vacuolar pathways of protein degradation in Saccharomyces cerevisiae J. Biol. Chem. 271 1996 27280 27284 (Pubitemid 26367280)
8. J. Myung, K.B. Kim, and C.M. Crews The ubiquitin-proteasome pathway and proteasome inhibitors Med. Res. Rev. 21 2001 245 273 (Pubitemid 32565494)
9. J.G. Delcros, M. Baudy-Floc'h, C. Prigent, and Y. Arlot-Bonnemains Proteasome inhibitors as therapeutic agents: current and future strategies Curr. Med. Chem. 10 2003 479 503 (Pubitemid 36221575)
10. K. Lindsten, V. Menéndez-Benito, M.G. Masucci, and N.P. Dantuma A transgenic mouse model of the ubiquitin/proteasome system Nat. Biotechnol. 21 2003 897 902 (Pubitemid 36936195)
11. D. Peer, J.M. Karp, S. Hong, O.C. Farokhzad, R. Margalit, and R. Langer Nanocarriers as an emerging platform for cancer therapy Nat. Nanotechnol. 2 2007 751 760 (Pubitemid 350223348)
12. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, and K. Hori Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review J. Control. Release 65 2000 271 284 (Pubitemid 30122932)
13. K. Kataoka, G.S. Kwon, M. Yokoyama, T. Okano, and Y. Sakurai Block copolymer micelles as vehicles for drug delivery J. Control. Release 24 1993 119 132 (Pubitemid 23161325)
14. A.S. Mikhail, and C. Allen Block copolymer micelles for delivery of cancer therapy: transport at the whole body, tissue and cellular levels J. Control. Release 138 2009 214 223
15. Y. Bae, and K. Kataoka Intelligent polymeric micelles fromfunctional poly(ethylene glycol)-poly(amino acid) block copolymers Adv. Drug Deliv. Rev. 61 2009 768 784
16. A. Lavasanifar, J. Samuel, and G. Kwon Poly(ethylene oxide)-block-poly(L- amino acid) micelles for drug delivery Adv. Drug Deliv. Rev. 54 2002 169 190 (Pubitemid 34230440)
17. Y. Matsumura, and K. Kataoka Preclinical and clinical studies of anticancer agent-incorporating polymer micelles Cancer Sci. 100 2009 572 579
18. R. Plummer, R.H. Wilson, H. Calvert, A.V. Boddy, M. Griffin, J. Sludden, M.J. Tilby, M. Eatock, D.G. Pearson, C.J. Ottley, Y. Matsumura, K. Kataoka, and T. Nishiya A phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours Br. J. Cancer 104 2011 593 598
19. A. Takahashi, Y. Yamamoto, M. Yasunaga, Y. Koga, J. Kuroda, M. Takigahira, M. Harada, H. Saito, T. Hayashi, Y. Kato, T. Kinoshita, N. Ohkohchi, I. Hyodo, and Y. Matsumura NC-6300, an epirubicin-incorporating micelle, extends the antitumor effect and reduces the cardiotoxicity of epirubicin Cancer Sci. 104 2013 920 992
20. E.R. Gillies, and J.M. Fréchet pH-responsive copolymer assemblies for controlled release of doxorubicin Bioconjug. Chem. 16 2005 361 368 (Pubitemid 40388212)
21. Y. Bae, S. Fukushima, A. Harada, and K. Kataoka Design of environment-sensitive supramolecular assemblies for intracellular drug delivery: polymeric micelles that are responsive to intracellular pH change Angew. Chem. Int. Ed. 42 2003 4640 4643 (Pubitemid 37271305)
22. Y. Bae, N. Nishiyama, S. Fukushima, H. Koyama, Y. Matsumura, and K. Kataoka Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy Bioconjug. Chem. 16 2005 122 130 (Pubitemid 40129685)
23. M. Yokoyama, G.S. Kwon, T. Okano, Y. Sakurai, T. Seto, and K. Kataoka Preparation of micelle-forming polymer-drug conjugates Bioconjug. Chem. 3 1992 295 301
24. Y. Bae, W.-D. Jang, N. Nishiyama, S. Fukushima, and K. Kataoka Multifunctional polymeric micelles with folate-mediated cancer cell targeting and pH-triggered drug releasing properties for active intracellular drug delivery Mol. BioSyst. 1 2005 242 250 (Pubitemid 41442434)
25. K. Khougaz, Z. Gao, and A. Eisenberg Determination of the critical micelle concentration of block copolymer micelles by static light scattering Macromolecules 27 1994 6341 6346
26. H. Hillaireau, and P. Couvreur Nanocarriers' entry into the cell: relevance to drug delivery Cell. Mol. Life Sci. 66 2009 2873 2896
27. R. Duncan, and S.C. Richardson Endocytosis and intracellular trafficking as gateways for nanomedicine delivery: opportunities and challenges Mol. Pharm. 9 2012 2380 2402
28. I.D. Johnson, H.C. Kang, and R.P. Haugland Fluorescent membrane probes incorporating dipyrrometheneboron difluoride fluorophores Anal. Biochem. 198 1991 228 237
29. M. Murakami, H. Cabral, Y. Matsumoto, S. Wu, M.R. Kano, T. Yamori, N. Nishiyama, and K. Kataoka Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting Sci. Transl. Med. 3 64 2011 64ra2
30. G.D. Bettignies, and O. Coux Proteasome inhibitors: dozens of molecules and still counting Biochimie 92 2010 1530 1545
31. N. Guo, and Z. Peng MG132, a proteasome inhibitor, induces apoptosis in tumor cells, Asia-Pac J. Clin. Oncol. 9 2013 6 11
32. H. Cabral, Y. Matsumoto, K. Mizuno, Q. Chen, M. Murakami, M. Kimura, Y. Terada, M.R. Kano, K. Miyazono, M. Uesaka, N. Nishiyama, and K. Kataoka Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size Nat. Nanotechnol. 6 2011 815 823
33. K. Neubert, S. Meister, K. Moser, F. Weisel, D. Maseda, K. Amann, C. Wiethe, T.H. Winkler, J.R. Kalden, R.A. Manz, and R.E. Voll The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis Nat. Med. 14 2008 748 755 (Pubitemid 351951516)
34. J.J. Everly, R.C. Walsh, R.R. Alloway, and E.S. Woodle Proteasome inhibition for antibody-mediated rejection Curr. Opin. Organ Transplant. 14 2009 662 666
35. A.S. Ahmed, J. Li, M. Ahmed, L. Hua, T. Yakovleva, M.H. Ossipov, G. Bakalkin, and A. Stark Attenuation of pain and inflammation in adjuvant-induced arthritis by the proteasome inhibitor MG132 Arthritis Rheum. 62 2010 2160 2169
36. P.J. Elliott, C.S. Pien, T.A. McCormack, I.D. Chapman, and J. Adams Proteasome inhibition: a novel mechanism to combat asthma J. Allergy Clin. Immunol. 104 1999 294 300 (Pubitemid 29420423)
37. N. Schmidt, E. Gonzalez, A. Visekruna, A.A. Kühl, C. Loddenkemper, H. Mollenkopf, S.H. Kaufmann, U. Steinhoff, and T. Joeris Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis Gut 59 2010 896 906
38. T.M. Zollner, M. Podda, C,. Pien, P.J. Elliott, R. Kaufmann, and W.H. Boehncke Proteasome inhibition reduces superantigenmediated T cell activation and the severity of psoriasis in a SCID-hu model J. Clin. Invest. 109 2002 671 679 (Pubitemid 34204846)
39. P.J. Elliott, T.M. Zollner, and W.H. Boehncke Proteasome inhibition: a new anti-inflammatory strategy J. Mol. Med. 81 2003 235 245 (Pubitemid 36578922)
40. A. Ludwig, M. Fechner, N. Wilck, S. Meiners, N. Grimbo, G. Baumann, V. Stangl, and K. Stan Potent anti-inflammatory effects of low-dose proteasome inhibition in the vascular system J. Mol. Med. 87 2009 793 802
41. M. Bentires-Alj, V. Barbu, M. Fillet, A. Chariot, B. Relic, N. Jacobs, J. Gielen, M.P. Merville, and V. Bours NFkappaB transcription factor induces drug resistance through MDR1 expression in cancer cells Oncogene 22 2003 90 97 (Pubitemid 36152887)
42. S.D. Catz, and J.L. Johnson Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer Oncogene 20 2001 7342 7351 (Pubitemid 33078205)
43. S. Fang, W. Zhu, Y. Zhang, Y. Shu, and P. Liu Paeoniflorin modulates multidrug resistance of a human gastric cancer cell line via the inhibition of NF-κB activation Mol. Med. Rep. 5 2012 351 356
44. T. Fujita, K. Washio, D. Takabatake, H. Takahashi, S. Yoshitomi, K. Tsukuda, Y. Ishibe, Y. Ogasawara, H. Doihara, and N. Shimizu Proteasome inhibitors can alter the signaling pathways and attenuate the P-glycoprotein-mediated multidrug resistance Int. J. Cancer 117 2005 670 682 (Pubitemid 41504558)
45. Y. Zhang, Y. Shi, X. Li, R. Du, G. Luo, L. Xia, W. Du, B. Chen, H. Zhai, K. Wu, and D. Fan Proteasome inhibitor MG132 reverses multidrug resistance of gastric cancer through enhancing apoptosis and inhibiting P-gp Cancer Biol. Ther. 7 2008 540 546 (Pubitemid 351847029)
46. M.R. Fekete, W.H. McBride, and F. Pajonk Anthracyclines, proteasome activity and multi-drug-resistance BMC Cancer 5 2005 114
47. Y. Ogiso, A. Tomida, S. Lei, S. Omura, and T. Tsuruo Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs Cancer Res. 60 2000 2429 2434 (Pubitemid 30262433)
48. S.T. Nawrocki, B. Sweeney-Gotsch, R. Takamori, and D.J. McConkey The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts Mol. Cancer Ther. 3 2004 59 70 (Pubitemid 39193679)
49. J. Jung, E.J. Kim, H.K. Chung, H.J. Park, S.Y. Jeong, and E.K. Choi c-Myc down-regulation is involved in proteasome inhibitor-mediated enhancement of radiotherapeutic efficacy in non-small cell lung cancer Int. J. Oncol. 40 2012 385 390
50. S. Goktas, Y. Baran, A.U. Ural, S. Yazici, E. Aydur, S. Basal, F. Avcu, A. Pekel, B. Dirican, and M. Beyzadeoglu Proteasome inhibitor bortezomib increases radiation sensitivity in androgen independent human prostate cancer cells Urology 4 2010 793 798